Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
78 studies found for:    regorafenib
Show Display Options
Rank Status Study
1 Recruiting Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Cetuximab (ERBITUX)
2 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
3 Completed Effect of Neomycin on the Pharmacokinetics of Regorafenib
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Neomycin
4 Recruiting Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
5 Recruiting Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: PF-03446962;   Drug: Regorafenib
6 Recruiting [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Condition: Colorectal Cancer
Intervention: Drug: Regorafenib
7 Recruiting Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Condition: Cancer of the Bile Duct
Intervention: Drug: Regorafenib
8 Recruiting Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Condition: Neoplasms
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Regorafenib (Stivarga, BAY73-4506)
9 Recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
10 Recruiting Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
Condition: Rectal Cancer
Interventions: Other: General condition;   Other: Blood pressure;   Other: Patient Reported Outcome;   Other: Clinical findings;   Other: Hematology/blood chemistry;   Other: Coagulation and fibrinolysis system;   Other: Urinalysis;   Other: Medication check;   Other: Adverse event;   Other: Thyroid function test;   Other: Contrast-enhanced torso CT;   Other: Brain MRI;   Drug: Dexamethasone;   Drug: Regorafenib;   Drug: Placebo;   Drug: Proton pump inhibitor
11 Recruiting Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Conditions: Pancreas Cancer;   Ovarian Cancer;   Melanoma;   Sarcoma
Intervention: Drug: Regorafenib
12 Recruiting Regorafenib Versus Placebo to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: Regorafenib/active;   Drug: Regorafenib/placebo
13 Not yet recruiting Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Conditions: Colon Adenocarcinoma;   Fatigue;   Palmar-Plantar Erythodysthesia;   Rectal Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Regorafenib;   Drug: Clobetasol Propionate;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
14 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
15 Recruiting Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Condition: Colorectal Neoplasms
Interventions: Device: SIR-Spheres;   Drug: Regorafenib
16 Recruiting Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
17 Active, not recruiting Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Condition: Advanced Chemorefractory Colorectal Adenocarcinoma
Intervention: Drug: regorafenib
18 Recruiting Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
19 Recruiting Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo
20 Not yet recruiting Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Conditions: Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Rectal Cancer
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years